Eisai and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA,of Australia has approved the humanized anti ...

The Therapeutic Goods Administration approves the drug Lecanemab, which can slow down cognitive decline in the early stages ...

A new treatment for early to mild Alzheimer’s disease has been registered with Australia’s pharmaceutical regulator, the Therapeutic Goods Administration.

LEQEMBI is a monoclonal antibody that is administered in a specialised centre via a one-hour intravenous infusion every two weeks and targets the underlying pathology of Alzheimer's disease. 1,2 ...

On 23 September 2025 the TGA made the decision to approve the registration of the lecanemab (LEQEMBI).What is LEQEMBI ...

Backed by the combined expertise of three USC schools, scientists are developing a new drug aimed at a previously unexplored ...

Participants were classed as having chronic insomnia if their medical records contained at least two insomnia diagnoses a ...

Several large studies this year compared outcomes for vaccinated and unvaccinated adults. The evidence points strongly to ...

A groundbreaking study from the Mayo Clinic reveals how chronic insomnia can accelerate cognitive decline and increase the ...